New York, USA – November 29, 2021 – As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics has launched a comprehensive list of immunohistochemistry antibodies for pathology. All the IHC antibodies are for research use only and not intended for diagnostic use.
Immunohistochemistry (IHC) is used in histology to detect the presence of specific protein marker that can assist with accurate tumor classification and diagnosis. It plays diagnostic, prognostic, or predictive roles in molecular pathology. IHC antibodies have been identified as the best reagents for use in immunohistochemistry on formalin-fixed paraffin sections. Diagnostics implement quality control for immunohistochemistry staining methods and interpretation in pathology laboratories.
Creative Diagnostics now offers immunohistochemistry antibodies to support pathology research. All the IHC antibodies are for research use only, and have been extensively tested and validated for immunohistochemistry on human tissues and are engineered to deliver consistent, specific, and sensitive stains. These new IHC antibodies are presented as prediluted format (ready-to-use and optimized for staining) as well as concentrated format (cost effective solution that can be optimized to meet the needs of each laboratory).
“Our IHC antibodies for pathology have been characterized at different concentrations against normal or diseased human tissues, plus additional relevant controls. In addition to traditional mouse monoclonal antibodies, Creative Diagnostics also provides high-quality recombinant rabbit monoclonal antibodies as either raw material for IHC antibody manufacturers or finished products for pathology IHC application.” said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.
Various IHC antibodies are available at Creative Diagnostics, such as the Anti-Human CA 19-9 monoclonal antibody. CA 19-9 is a secreted protein that is implicated in various cancers. It is overexpressed in salivary gland mucoepidermoid carcinomas and gastric, pancreatic, and colonic (gastrointestinal) adenocarcinomas, but is not expressed in breast, kidney, and prostate carcinomas. CA 19-9 staining is also implicated in Mirizzi’s Syndrome or other bile duct and liver diseases. This antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods.
Another example is Anti-Human A-1-Antichymotrypsin monoclonal antibody. Alpha-1-Antichymotrypsin (AACT or ACT) is a protease inhibitor that is proposed to act as an anti-inflammatory agent and control immunologic functions. AACT is expressed in mast cells, endothelial cells, and breast and intestinal epithelial cells. Other studies have also found AACT overexpression in neural tissues of those affected by Alzheimer’s disease. The major application of AACT labelling is to identify histiocytes and histiocyte-derived cancer cells. Some reports have found acinar pancreatic and salivary cancers to be stained by a-AACT. This antibody can be used to qualitatively identify the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods.
If you want to know more details about immunohistochemistry antibodies, please visit Creative Diagnostics at https://www.creative-diagnostics.com.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers’ assay development and manufacturing needs.